The impact of chronic kidney disease Stages 3-5 on pregnancy outcomes.
chronic renal insufficiency
hypertension
pregnancy
proteinuria
Journal
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402
Informations de publication
Date de publication:
09 11 2021
09 11 2021
Historique:
received:
27
01
2020
pubmed:
15
12
2020
medline:
20
1
2022
entrez:
14
12
2020
Statut:
ppublish
Résumé
Contemporaneous data are required for women with chronic kidney disease (CKD) Stages 3-5 to inform pre-pregnancy counselling and institute appropriate antenatal surveillance. A retrospective cohort study in women with CKD Stages 3-5 after 20 weeks' gestation was undertaken in six UK tertiary renal centres in the UK between 2003 and 2017. Factors predicting adverse outcomes and the impact of pregnancy in accelerating the need for renal replacement therapy (RRT) were assessed. There were 178 pregnancies in 159 women, including 43 women with renal transplants. The live birth rate was 98%, but 56% of babies were born preterm (before 37 weeks' gestation). Chronic hypertension was the strongest predictor of delivery before 34 weeks' gestation. Of 121 women with known pre-pregnancy hypertension status, the incidence of delivery before 34 weeks was 32% (31/96) in women with confirmed chronic hypertension compared with 0% (0/25) in normotensive women. The risk of delivery before 34 weeks doubled in women with chronic hypertension from 20% [95% confidence interval (CI) 9-36%] to 40% (95% CI 26-56%) if the gestational fall in serum creatinine was <10% of pre-pregnancy concentrations. Women with a urinary protein:creatinine ratio >100 mg/mmol prior to pregnancy or before 20 weeks' gestation had an increased risk for birthweight below the 10th centile (odds ratio 2.57, 95% CI 1.20-5.53). There was a measurable drop in estimated glomerular filtration rate (eGFR) between pre-pregnancy and post-partum values (4.5 mL/min/1.73 m2), which was greater than the annual decline in eGFR prior to pregnancy (1.8 mL/min/1.73 m2/year). The effect of pregnancy was, therefore, equivalent to 1.7, 2.1 and 4.9 years of pre-pregnancy renal disease in CKD Stages 3a, 3b and 4-5, respectively. The pregnancy-associated decline in renal function was greater in women with chronic hypertension and in those with a gestational fall in serum creatinine of <10% of pre-pregnancy concentrations. At 1 year post-partum, 46% (58/126) of women had lost ≥25% of their pre-pregnancy eGFR or required RRT. Most women with renal transplants had CKD Stage 3 and more stable renal function prior to pregnancy. Renal transplantation was not independently associated with adverse obstetric or renal outcomes. Contemporary pregnancies in women with CKD Stages 3-5 are complicated by preterm delivery, low birthweight and loss of maternal renal function. Chronic hypertension, pre- or early pregnancy proteinuria and a gestational fall in serum creatinine of <10% of pre-pregnancy values are more important predictors of adverse obstetric and renal outcome than CKD Stages 3-5. Pregnancy in women with CKD Stages 3-5 advances the need for dialysis or transplantation by 2.5 years.
Sections du résumé
BACKGROUND
Contemporaneous data are required for women with chronic kidney disease (CKD) Stages 3-5 to inform pre-pregnancy counselling and institute appropriate antenatal surveillance.
METHODS
A retrospective cohort study in women with CKD Stages 3-5 after 20 weeks' gestation was undertaken in six UK tertiary renal centres in the UK between 2003 and 2017. Factors predicting adverse outcomes and the impact of pregnancy in accelerating the need for renal replacement therapy (RRT) were assessed.
RESULTS
There were 178 pregnancies in 159 women, including 43 women with renal transplants. The live birth rate was 98%, but 56% of babies were born preterm (before 37 weeks' gestation). Chronic hypertension was the strongest predictor of delivery before 34 weeks' gestation. Of 121 women with known pre-pregnancy hypertension status, the incidence of delivery before 34 weeks was 32% (31/96) in women with confirmed chronic hypertension compared with 0% (0/25) in normotensive women. The risk of delivery before 34 weeks doubled in women with chronic hypertension from 20% [95% confidence interval (CI) 9-36%] to 40% (95% CI 26-56%) if the gestational fall in serum creatinine was <10% of pre-pregnancy concentrations. Women with a urinary protein:creatinine ratio >100 mg/mmol prior to pregnancy or before 20 weeks' gestation had an increased risk for birthweight below the 10th centile (odds ratio 2.57, 95% CI 1.20-5.53). There was a measurable drop in estimated glomerular filtration rate (eGFR) between pre-pregnancy and post-partum values (4.5 mL/min/1.73 m2), which was greater than the annual decline in eGFR prior to pregnancy (1.8 mL/min/1.73 m2/year). The effect of pregnancy was, therefore, equivalent to 1.7, 2.1 and 4.9 years of pre-pregnancy renal disease in CKD Stages 3a, 3b and 4-5, respectively. The pregnancy-associated decline in renal function was greater in women with chronic hypertension and in those with a gestational fall in serum creatinine of <10% of pre-pregnancy concentrations. At 1 year post-partum, 46% (58/126) of women had lost ≥25% of their pre-pregnancy eGFR or required RRT. Most women with renal transplants had CKD Stage 3 and more stable renal function prior to pregnancy. Renal transplantation was not independently associated with adverse obstetric or renal outcomes.
CONCLUSIONS
Contemporary pregnancies in women with CKD Stages 3-5 are complicated by preterm delivery, low birthweight and loss of maternal renal function. Chronic hypertension, pre- or early pregnancy proteinuria and a gestational fall in serum creatinine of <10% of pre-pregnancy values are more important predictors of adverse obstetric and renal outcome than CKD Stages 3-5. Pregnancy in women with CKD Stages 3-5 advances the need for dialysis or transplantation by 2.5 years.
Identifiants
pubmed: 33313680
pii: 6032223
doi: 10.1093/ndt/gfaa247
pmc: PMC8577624
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2008-2017Subventions
Organisme : Department of Health
ID : RP-2014-05-019
Pays : United Kingdom
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.
Références
J Am Soc Nephrol. 2015 Aug;26(8):2011-22
pubmed: 25766536
Kidney Int. 1998 Dec;54(6):2056-63
pubmed: 9853271
Int J Womens Health. 2016 Jul 14;8:273-85
pubmed: 27471410
BMJ. 2008 Jan 26;336(7637):211-5
pubmed: 18219043
BMJ. 2014 Apr 15;348:g2301
pubmed: 24735917
J Clin Med. 2018 Nov 05;7(11):
pubmed: 30400594
N Engl J Med. 1996 Jul 25;335(4):226-32
pubmed: 8657238
Br J Obstet Gynaecol. 1981 Jan;88(1):10-7
pubmed: 7459286
Pregnancy Hypertens. 2019 Jan;15:42-50
pubmed: 30825926
Ren Fail. 2004 Jan;26(1):29-34
pubmed: 15083918
Kidney Int. 2017 Jun;91(6):1464-1472
pubmed: 28233609
Public Health Nutr. 2015 Dec;18(18):3349-54
pubmed: 25743030
J Hypertens. 2015 Jan;33(1):96-105
pubmed: 25255393
Am J Obstet Gynecol. 2016 Nov;215(5):628.e1-628.e7
pubmed: 27372269
Am J Kidney Dis. 2007 Jun;49(6):753-62
pubmed: 17533018
Kidney Int. 2014 Jan;85(1):49-61
pubmed: 24284513
J Nephrol. 2018 Dec;31(6):953-960
pubmed: 30027380
Semin Perinatol. 2017 Aug;41(5):318-322
pubmed: 28669415
Kidney Int. 2016 Apr;89(4):874-85
pubmed: 26924064
BMJ Open Diabetes Res Care. 2016 Apr 11;4(1):e000154
pubmed: 27110365
Am J Obstet Gynecol. 2016 Jul;215(1):103.e1-103.e14
pubmed: 26772790